SLGL News and Press, Sol-Gel Technologies Ltd. From 04/27/21

Sol-Gel Technologies ([[SLGL]] -21.1%) has shed more than a fifth in value after announcing that the company received no notification from the FDA regarding its marketing application for EPSOLAY (benzoyl peroxide) 5% topical cream for adults with Inflammatory lesions of rosacea.However, ...

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an upda...

InspireMD (NSPR) -19%.Reviva Pharmaceuticals (RVPH) -17%.RealNetworks RNWK -16% on preliminary estimates for its first-quarter, stock offering.Mechanical Technology (MKTY) -10% after subsidiary announces newest addition of the PBS-4100+ portable vibration and balancing system.S...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Sol-Gel Technologies (SLGL): FY net loss of $29.3M.Revenue of $8.8M (-61.6% Y/Y) beats by $0.5M.Press Release For further details see: Sol-Gel Technologies reports FY 2020 results

• Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively • Top-line generic product revenue of $8. 7 million in fiscal 2020 ...

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...

NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...

Sol-Gel Technologies's ([[SLGL]] +0.4%) marketing application seeking approval for Twyneo (benzoyl peroxide and tretinoin), for the treatment of acne vulgaris, has been accepted the the FDA. Action date is set at August 1, 2021.Twyneo is a proprietary fixed-dose combination of ...

- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatolog...